Research Topics
Genomes and Genes | D C BaumgartSummaryAffiliation: Humboldt University Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Crohn's diseaseDaniel C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, Berlin, Germany
Lancet 380:1590-605. 2012....- Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when?Daniel C Baumgart
Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center Virchow Hospital, Medical School of Humboldt University of Berlin, Berlin, Germany
Dig Dis 29:32-5. 2011..Dysplasia can be graded by the Vienna or Riddell classification. Colectomy is recommended for patients with flat high-grade dysplasia confirmed by an expert gastrointestinal pathologist... 
[Mucosal dendritic cells: reaching out for the unknown (antigen)]D C Baumgart
, Campus Virchow-Klinikum, , Germany
Z Gastroenterol 40:375-7. 2002- Personal digital assistants in health care: experienced clinicians in the palm of your hand?Daniel C Baumgart
Department of Medicine, Charite Medical School, Virchow Hospital, Humboldt University of Berlin, D 13344 Berlin, Germany
Lancet 366:1210-22. 2005..A personal perspective and an introduction to medical PDA applications, software, guidelines, and programmes for health-care professionals is also provided... - Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C Baumgart
Department of Medicine, Divisions of Gastroenterology and Hepatology, Charité Medical School of the Humboldt University of Berlin, Germany
Inflamm Bowel Dis 16:620-9. 2010..Visilizumab is a humanized IgG(2) monoclonal anti-CD3 antibody. We evaluated its safety and dose response in severe intravenous steroid-refractory ulcerative colitis (UC)... 
The diagnosis and treatment of Crohn's disease and ulcerative colitisDaniel C Baumgart
Medizinische Klinik mit Schwerpunkt Gastroenterologie und Hepatologie, Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
Dtsch Arztebl Int 106:123-33. 2009..The purpose of this review article is to heighten awareness of these diseases among physicians whose primary clinical activities lie outside gastroenterology...- Inflammatory bowel disease: cause and immunobiologyDaniel C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
Lancet 369:1627-40. 2007..Implications for novel therapies, which are discussed in detail in the second paper in this Series, are covered briefly... - Inflammatory bowel disease: clinical aspects and established and evolving therapiesDaniel C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
Lancet 369:1641-57. 2007..Finally, we summarise the practical aspects of standard therapies including dosing, precautions, and side-effects... - Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's diseaseDaniel C Baumgart
Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical School, Humboldt University of Berlin, Berlin, Germany
Am J Gastroenterol 104:868-76. 2009..Monoclonal antibodies to CD3 and CD4 T-cell receptors are evolving for Crohn's disease (CD) and ulcerative colitis. Their administration is often associated with a cytokine release syndrome (CRS)... - What's new in inflammatory bowel disease in 2008?Daniel C Baumgart
Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Augustenburger Platz 1, Berlin, Germany
World J Gastroenterol 14:329-30. 2008.... - Virchow's nodeDaniel C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology, , Medical School of the Humboldt University of Berlin, Berlin, Germany
Lancet 370:1568. 2007 - CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitisDaniel C Baumgart
Charite Medical Center Virchow Hospital, Department of Medicine, Division of Gastroenterology and Hepatology Medical School of the Humboldt University of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Curr Opin Investig Drugs 11:571-6. 2010.... - Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuverDaniel C Baumgart
Division of Hepatology and Gastroenterology, , Virchow Hospital, Medical School, Humboldt-University of Berlin, D-13344 Berlin, Germany
Gastrointest Endosc 61:473-5. 2005 - Intestinal barrier functionDaniel C Baumgart
Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Department of Medicine, Division of Hepatology and Gastroenterology, Germany
Curr Opin Clin Nutr Metab Care 5:685-94. 2002..New therapeutic approaches including probiotics and peptides to restore disrupted barrier function are evolving... - Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitisSaskia Thomas
Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Berlin, Germany
Am J Physiol Gastrointest Liver Physiol 301:G1083-92. 2011.... - [Biologic therapy of inflammatory bowel disease]D C Baumgart
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Interdisziplinäres Stoffwechselzentrum, Universitatsklinikum Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin
Z Gastroenterol 41:1017-32. 2003..Based on the data discussed, it seems that biologicals will play an important role in managing inflammatory bowel disease in the near future... - Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel diseaseD C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical School of the Humboldt University of Berlin, D 13344 Berlin, Germany
Clin Exp Immunol 157:423-36. 2009..001 versus P < 0.01, respectively). Our data suggest an aberrant LPS response of mDC in IBD patients, resulting in an inflammatory phenotype and possibly intestinal homing in acute flares... - Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitisD C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology Department of Surgery General Internal Medicine Outpatient Clinic, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
Clin Exp Immunol 166:46-54. 2011..We speculate that the impaired IFN-α secretion may relate to the hypothesized defect in innate immunity in IBD and could also impact upon the generation of regulatory T cells (T(reg) )... - Current biological therapies for inflammatory bowel diseaseDaniel C Baumgart
Charite Medical Center Virchow Hospital, Medical School of the Humboldt University, Department of Medicine, Division of Hepatology and Gastroenterology, D 13344 Berlin, Germany
Curr Pharm Des 10:4127-47. 2004..Based on the data discussed, it appears that biologics may play an increasing role in managing inflammatory bowel disease in the near future... - Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patientsDaniel C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology, Humboldt University of Berlin, Germany
Inflamm Bowel Dis 17:2512-20. 2011..Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (IBD)... - Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cellsD C Baumgart
Charité Medical Centre Virchow Hospital, Medical School of the Humboldt University, Department of Medicine, Division of Hepatology and Gastroenterology, D 13344 Berlin, Germany
Gut 54:228-36. 2005..Dendritic cells (DC) have been implicated in this process in various animal models, but data on human DC in IBD are very limited... - IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meetingDaniel C Baumgart
Charite Medical School, Virchow Hospital, Humboldt University of Berlin, Germany
Inflamm Bowel Dis 17:639-44. 2011.... - The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel diseaseDaniel C Baumgart
Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical School, Humboldt University of Berlin, Berlin, Germany
Digestion 76:196-202. 2007..Therefore, the study of candidate genes involved in host pathogen interactions is of key interest... - Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferationS Thomas
Department of Medicine, Division of Gastroenterology and Hepatology, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Berlin, Germany
Clin Exp Immunol 156:78-87. 2009.... - Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitisC Buning
Department of Gastroenterology, Hepatology and Endocrinology, Charite, Campus Mitte, Universitatsmedizin Berlin, Berlin, Germany
Aliment Pharmacol Ther 26:1025-33. 2007..A recent study reported that a non-synonymous single nucleotide polymorphism (rs11209026, p.Arg381Gln) located in the IL23R gene is a protective marker for inflammatory bowel disease... - No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: a study in 3 independent European cohortsCarsten Buning
Department of Gastroenterology, Hepatology and Endocrinology, Charite, Campus Mitte, Universitatsmedizin Berlin, Germany
Inflamm Bowel Dis 14:332-7. 2008..The aim of this study was to analyze the frequency of p.C10X in 3 independent European (IBD) cohorts from Germany, Hungary, and the Netherlands... - Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanismsA U Dignass
Department of Medicine, Division of Hepatology and Gastroenterology, Charité Medical School Virchow Hospital, Berlin, Germany
Aliment Pharmacol Ther 20:9-17. 2004..A better understanding of and enhancement of intestinal repair mechanisms may thus provide future approaches for the treatment of inflammatory bowel disease... - Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel diseaseD C Baumgart
, Medical School of the Humboldt University of Berlin, Department of Medicine, Division of Hepatology and Gastroenterology, Berlin, Germany
Aliment Pharmacol Ther 17:1273-81. 2003..7%), tremor or paraesthesias (n = 3, 9.7%), hyperkalaemia (n = 1, 3.2%), hypertension (n = 1, 3.2%) and an opportunistic infection (n = 1, 3.2%). CONCLUSION: Oral tacrolimus is safe and effective in refractory inflammatory bowel disease... - Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signalingAndreas Sturm
Department of Hepatology and Gastroenterology, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, D 13353 Berlin, Germany
Infect Immun 73:1452-65. 2005.... - Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancerUta Berndt
Department of Medicine, Division of Gastroenterology and Hepatology, Charite Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
Cancer Res 68:880-8. 2008..Thus, topological proteomic analysis may help to unravel the role of the adaptive immune system in colorectal cancer and aid the development of new antitumor immunotherapy approaches... - Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-upDaniel C Baumgart
Department of Medicine, Division of Hepatology and Gastroenterology, , Virchow Hospital, Medical School of the Humboldt-University of Berlin, Germany
Am J Gastroenterol 101:1048-56. 2006..6%), tremor or paresthesias (n = 5, 9.4%), hyperkalemia (n = 1, 1.9%), hypertension (n = 1, 1.9%), and opportunistic infections (n = 2, 3.8%). CONCLUSION: Long-term tacrolimus therapy appears safe and effective in refractory IBD... - [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?]B T Tanczos
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin
Z Gastroenterol 44:609-10. 2006 - Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathwaysA Grabig
Charite Universitatsmedizin Berlin, Campus Virchow Clinic, Department of Hepatology and Gastroenterology, Augustenburger Platz 1, D 13353 Berlin, Germany
Infect Immun 74:4075-82. 2006..In conclusion, our data provide evidence that E. coli Nissle 1917 ameliorates experimental induced colitis in mice via TLR-2- and TLR-4-dependent pathways... - CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathwayAndreas Sturm
Department of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow, Augustenburger Platz 1, D 13353 Berlin, Germany
Cytokine 29:42-8. 2005..As intestinal epithelial cells have been recently shown to produce CXCL8, the aim of this study was to identify functional activities of CXCL8 on intestinal epithelial cells... - Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanismDaniel C Baumgart
Department of Medicine, Division of Hepatology and Gastroenterology, , Medical School of the Humboldt-University of Berlin, Germany
Scand J Gastroenterol 40:958-64. 2005.... - Endocytoscopy for the detection of microstructural features in adult patients with celiac sprue: a prospective, blinded endocytoscopy-conventional histology correlation studyHeiko Pohl
Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center, Virchow Hospital, Medical School of Humboldt University of Berlin, Berlin, Germany
Gastrointest Endosc 70:933-41. 2009..Endocytoscopy (EC) is a novel technique that allows magnified live inspection of the intestinal mucosa... - Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1aEckart Schott
Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical School, Humboldt University of Berlin, Berlin, Germany
World J Gastroenterol 13:3638-40. 2007.... - Viral gastroenteritis in adultsAlexander J Eckardt
Deutsche Klinik fur Diagnostik, Division of Gastroenterology and Hepatology, D 65191 Wiesbaden, Germany
Recent Pat Antiinfect Drug Discov 6:54-63. 2011..Special emphasis is put on current and future vaccines... - Impact of pain on health-related quality of life in patients with inflammatory bowel diseaseAnja Schirbel
Division of Gastroenterology and Hepatology, Department of Medicine, Charite Campus Virchow Clinic, Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
World J Gastroenterol 16:3168-77. 2010..To evaluate intensity, localization and cofactors of pain in Crohn's disease and ulcerative colitis patients in connection with health-related quality of life (HRQOL) and disease activity... - Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitisDaniel C Baumgart
Department of Medicine, , Medical School of the Humboldt-University of Berlin, D-13344 Berlin, Germany
Inflamm Bowel Dis 10:421-4. 2004..Complete non-scarring skin restitution without side effects was accomplished in both cases. Low dose oral tacrolimus provides a valuable alternative treatment option for IBD patients with refractory pyoderma gangrenosum... - Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndromeDaniel C Baumgart
, Humboldt University of Berlin, Germany
Am Fam Physician 68:151-2. 2003 - Lipoxins and resolvins in inflammatory bowel diseaseKarsten H Weylandt
Department of Medicine, Division of Hepatology and Gastroenterology, Charité Medical School Virchow Hospital, Humboldt University of Berlin, Germany
Inflamm Bowel Dis 13:797-9. 2007..In this article we discuss the emerging knowledge on the effects of lipoxins and resolvins on various inflammatory pathways and why they are promising candidates for novel therapies of human inflammatory bowel disease... - Recognition and appropriate management of dysplasia-associated lesions or masses in inflammatory bowel disease--experience does matterDaniel C Baumgart
Gastrointest Endosc 66:530-2. 2007 - Autoregulation of Th1-mediated inflammation by twist1Uwe Niesner
German Rheumatism Research Center Berlin, 10117 Berlin, Germany
J Exp Med 205:1889-901. 2008....